medico intercontinental has released its audited financial results for the quarter and year ended March 31, 2026. The Board of Directors approved the results during a meeting held on May 22, 2026. The company reported a decline in standalone net profit for the full year, while consolidated figures reflected a shift to a net loss position.

Standalone Financial Performance

For the financial year ended March 31, 2026, the company reported a total revenue of ₹5680.62 lakh, compared to ₹6763.75 lakh in the previous year. Total expenses for the year stood at ₹5368.98 lakh, lower than the ₹6406.20 lakh recorded in the prior year. The net profit for the period after tax was ₹218.36 lakh, a decrease from ₹256.58 lakh in the corresponding period of the previous year.

In the quarter ended March 31, 2026, the standalone net profit after tax was ₹42.41 lakh. Revenue from operations for the quarter was ₹1582.34 lakh, and total expenses amounted to ₹1582.23 lakh.

Consolidated Financial Results

On a consolidated basis, the group reported a total revenue of ₹8535.45 lakh for the year ended March 31, 2026, down from ₹9573.23 lakh in the previous year. Total expenses increased to ₹9469.49 lakh from ₹8891.12 lakh. The group recorded a net loss of ₹1098.04 lakh for the current year, contrasting with a net profit of ₹505.73 lakh in the previous year.

For the quarter ended March 31, 2026, the consolidated net loss was ₹233.25 lakh. Revenue from operations for the quarter was ₹2248.53 lakh, while total expenses were ₹2415.11 lakh.

Key Financial Metrics

The following table summarizes the key standalone financial figures for the year:

Board Decisions

In addition to the financial results, the Board approved the re-appointment of M/s. MJV & Co, Chartered Accountants, Ahmedabad as the Internal Auditor of the company for the financial year 2026-27. The Board also approved various corporate policies for disclosure on the company's website.

Medico Intercontinental Limited has notified BSE Limited of an upcoming Board of Directors meeting, scheduled to be held on Friday, May 22, 2026. The meeting will take place at the company's registered office located at 1-5th Floor, Aditraj Arcade, Nr Karma Shreshtha Tower, 100 Ft Rd, Satellite, Ahmedabad, Gujarat – 380015. The intimation was issued on May 14, 2026, in compliance with Regulations 29, 30, and 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Board Meeting Agenda

The primary purpose of the meeting is to consider, approve, and take on record the Audited Financial Results of the company for the quarter and financial year ended March 31, 2026. The results will cover both Standalone and Consolidated financials. Any other business items as per the agenda circulated may also be addressed during the meeting.

Key details of the scheduled board meeting are outlined below:

Trading Window Closure

In continuation of its earlier intimation dated March 30, 2026, Medico Intercontinental Limited has confirmed that the trading window for dealing in the securities of the company has been closed with effect from April 1, 2026. This closure applies to all designated persons, including insiders, in compliance with the provisions of the SEBI (Prohibition of Insider Trading) Regulations and the company's Code of Conduct for Prevention of Insider Trading.

The trading window will remain closed until the conclusion of 48 hours after the declaration of the financial results for the quarter and financial year ended March 31, 2026. The intimation was signed by Samir D Shah, Managing Director (DIN: 03350268), on behalf of Medico Intercontinental Limited.